Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

By sjmartinez • February 24, 2023

Sofen H, Bissonnette R, Yosipovitch G, Silverberg JI, Tyring S, Loo WJ, Zook M, Lee M, Zou L, Jiang GL, Paolini JF. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. doi: 10.1016/j.eclinm.2023.101826. PMID: 36816342; PMCID: PMC9932343.

Tags: Dermatology, Olive View DoM, Publications

Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic review

Passero L, Simon TA, Zhong Y, Zhuo J, Varga S, Armstrong AW. Role of real-world evidence from patient registries for psoriasis in decision-making: a systematic[...]

Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination

Wang J, Patel S, Kolker S, Bennett RG. Onycholemmal Carcinoma Excised by Mohs Micrographic Surgery With Immediate Frozen Section Bone Examination. Dermatol Surg. 2025 Dec[...]

Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis

Yan MJ, Jiang YC, Wongvibulsin S, Chen ST. Assessing public interest in artificial intelligence in dermatology: A Google Trends analysis. JID Innov. 2025 Nov 17;6(2):100435.[...]